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ABSTRACT
The ACSL A/G polymorphism is associated with endurance trainability. 
Previous studies have demonstrated that homozygotes of the minor AA 
allele had a reduced maximal oxygen consumption response to training 
compared to the common GG allele homozygotes, and that the ACSL A/G 
single nucleotide polymorphism explained 6.1% of the variance in the 
VO2max response to endurance training. The contribution of ACSL single 
nucleotide polymorphism to endurance trainability was shown in non-
athletes, however, its potential role in professional athletes is not clear. 
Moreover, the genetic basis to anaerobic trainability is even less studied. 
Therefore, the aim of the present study was to examine the prevalence of 
ACSL single nucleotide polymorphism among professional Israeli long 
distance runners (n=59), middle distance runners (n=31), sprinters and 
jumpers (n=48) and non-athletic controls (n=60). The main finding of 
the present study was that the ACSL1 AA genotype, previously shown to 
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be associated with reduced endurance trainability, was not higher among 
sprinters and jumpers (15%) compared to middle- (16%) and long-dis-
tance runners (15%). This suggests that in contrast to previous studies 
indicating that the ACSL1 single nucleotide polymorphism may influence 
endurance trainability among non-athletic individuals, the role of this 
polymorphism among professional athletes is still not clear.
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INTRODUCTION
Long-chain-fatty-acid – CoA ligase 1 is an enzyme that in humans is 
encoded by the ACSL1 gene [12, 13]. ACSL1 exhibits an important poten-
tial relevance to the adaptation to regular exercise. ACSL1 contributes most 
of the acyl-CoA synthetase activity in adipose tissue and is highly expressed 
also in skeletal muscles and in the heart. ACSL1 encodes for an enzyme 
that is involved in the partitioning of fatty acids and the control of lipid 
influx but, even more importantly, the control of carbohydrate efflux [8]. It 
plays a key role in normal insulin metabolism and fatty acid-induced insu-
lin resistance. A SNP in ACSL1 has been associated with fasting glucose, 
insulin resistance, and the presence of metabolic syndrome, particularly in 
the presence of a high-fat diet [10]. Besides its possible relevance to habit-
ual physical activity and exercise, studies have shown that homozygotes of 
the rs6552828 minor allele (A/A) had 125 ml/min (28%) and 63 ml/min 
(17%) lower VO2max responses to endurance exercise training than the 
common allele homozygotes (G/G) and heterozygotes (A/G), respectively. 
In a single-SNP analyses, rs6552828 explained 6.1% of the variance in the 
VO2max response to training [3]. Therefore, the potential contributing role 
of the ACSL1 gene in aerobic metabolism at the adypocite, cardiomyocite, 
liver and skeletal muscle fiber level [4, 5–7, 9, 11] highlights its potential to 
explain individual variability in endurance performance, as well as in some 
health-related phenotypes. 
While the contribution of ACSL1 single nucleotide polymorphism to 
endurance trainability was shown in non-athletes, its potential role in pro-
fessional athletes is less studied. Moreover, the genetic basis to anaerobic 
trainability is even less studied. Therefore, the aim of the present study 
was to examine the prevalence of ACSL1 SNP among professional Israeli 
long distance runners, middle distance runners, sprinters and jumpers. We 
hypothesized that the ACSL1 AA genotype associated with reduced endur-
ance trainability would be higher among sprinters and jumpers.
MATERIALS AND METHODS
Subjects
One hundred and thirty-eight male athletes [59 long distance runners 
(LDR), 31 middle distance runners (MDR), 48 sprinters and jumpers (S/J)], 
and 60 non-athletic controls participated in the study. All athletes competed 
in national and/or international level meets on a regular basis. Athletes’ data 
are presented in Table 1.
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Table 1. Athletes’ data.
 Group N Main even Age (Mean±SD, Range)
LDR 59 5000m–marathon 32.4±9.5 (20–50)
MDR 31 800–1500m 32.3±15.0 (17–55)
S/J 48 100–200m, jumps 30.5±13.7 (17–49)
Control 60 nr 26.4±5.8 (19–29)
LDR – long distance runners; MDR – middle distance runners; S/J – sprinters and jumpers
The study was approved by the Institutional Review Board of the Hillel 
Yaffe Medical Center, Hadera, Israel, according to the Declaration of Hel-
sinki. A written informed consent was obtained from all participants.
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood or 
buccal cells according to the salting-out procedure. Genotypes were deter-
mined using the Taqman allelic discrimination assay. The Assay-by-Design 
service (https://www.thermofisher.com /il/en/home.html) was used to set 
up a Taqman allelic discrimination assay for the ACSL (rs6552828 A/G), 
Primers and probe sequences are given in Table 2.
Table 2. Primers and probe sequences for ACSL (rs6552828 A/G) Taqman allelic 
discrimination assays.
Primer sequences Probe sequences
Forward Reverse Forward: VIC Reverse: FAM
pdUGpdUApdCpd
UpdUpdUpdCpdUp
dCpdUpdCpdCAAp
dCA
pdCpdUGpdUApdC
pdUpdUpdUpdCpd
UpdUpdUpdCpdCA
ApdCA
CGGCTGCATCTA
GGATCTCAA
TGCATAAACTTT
AAACCAACCAC
CA
The Polymerase Chain Reaction (PCR) mixture included 5 ng genomic 
DNA, 0.125 μl TaqMan assay (40*, ABI), 2.5 μl Master mix (ABI) and 2.375 μl 
water. PCR was performed in 96 well PCR plates in an ABI 7300 PCR sys-
tem (Applied Biosystems Inc., Foster City, CA, USA) and consisted of initial 
denaturation for 5 min at 95  °C, and 40 cycles with denaturation of 15 s at 
95  °C and annealing and extension for 60 s at 63  °C. Results were analyzed by 
the ABI Taqman 7900HT using the sequence detection system 2.22 software 
(Applied Biosystems Inc., Foster City, CA, USA).
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Statistics
The SPSS statistical package, version 20.0, was used to perform all statistical 
evaluations (SPSS, Chicago, IL, USA). A χ2-test was used to confirm that 
the observed genotype frequencies were within the Hardy-Weinberg equi-
librium, and to compare allele and genotype frequencies between athletes 
and controls, as well as between athletes from different competitive levels. 
If observed or expected values included a cell with a value of 5, we used 
Fisher’s exact test to compare alleles and genotype frequencies. 
RESULTS
The complete data on allele and genotype frequencies are presented in 
Table 3. The genotype subtype did not differ by age or sex. ACSL genotypes 
were in agreement with the Hardy-Weinberg equilibrium for all groups 
(p = 0.917 for Controls, p = 0.843 for S/J, p = 0.856 for MDR; p = 0.930 for 
LDR).
Table 3. ACSL A/G (rs6552828) Genotype and allele frequencies (%).
Control S/J MDR LDR
n 60 48 31 59
AA 7(12) 7(15) 5(16) 9(15)
AG 24(40) 23(48) 11(35) 30(51)
GG 29(48) 18(38) 15(48) 20(34)
A allele 38(32) 37(39) 21(34) 48(41)
G allele 82(68) 59(61) 41(66) 70(59)
S/J – sprinters and jumpers; MDR – middle d istance runners; LDR – long distance runners
The frequency of the ACSL AA genotype carriers, which is related to reduced 
VO2max response to training, was not significantly different among LDR, 
MDR, S/J and controls (Figure 1).
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Figure 1. ACSL A/G genotype frequencies among S/J, MDR, LDR, and controls. 
 
DISCUSSION
The present study examined the prevalence of ACSL1 SNP among profes-
sional Israeli long distance runners, middle distance runners, sprinters and 
jumpers. The main finding of the study was that in contrast to our hypothe-
sis, the ACSL1 AA genotype, previously shown to be associated with reduced 
endurance trainability, was not higher among sprinters and jumpers com-
pared to long-distance runners.
The ACSL A/G polymorphism is associated with endurance trainability. 
It was previously demonstrated that homozygotes of the minor AA allele 
had a reduced VO2max response to training compared to the common GG 
allele homozygotes, and that the ACSL A/G single nucleotide poly morphism 
explained 6.1% of the variance in the VO2max response to  endurance 
 training [3]. However, while this association was found in non-athletic indi-
viduals, the linkage between the ACSL1 single nucleotide polymorphism 
and endurance trainability among professional athletes, and in particularly, 
among a homogeneous group of long-distance runners, is much less clear. 
The ACSL SNP may vary among different populations of long-distance 
runners. Consistent with that the frequency of the AA genotype (associ-
ated with reduced endurance trainability) among native Israeli long-distance 
runners was higher (24%) than the frequencies reported among  Spanish 
 endurance athletes (17.1%) and lower compared to Chinese (31.3%) 
 endurance athletes [14]. Moreover, we recently studied the frequency of the 
ACSL genotype among Israeli long-distance runners of Ethiopian and non-
Ethiopian origin. The Ethiopian Beta Israel community consist only about 
126  |  S Ben-Zaken, Y Meckel, D Nemet, A Eliakim
1.7% of the overall Israeli population, but their dominance in Israeli long-
distance record table is dramatic (e.g. between 50–66% of the 30 all-time 
best male results in the marathon and half-marathon). We found that the 
frequency of the AA genotype carriers among Israeli long-distance  runners 
of Ethiopian origin was significantly lower (8%) compared to the non- 
Ethiopian Origin Israeli runners (24%) [2]. Thus, fewer long-distance run-
ners of Ethiopian origin had a genetic predisposition for reduced response 
to aerobic training. Interestingly, among the non-Ethiopian origin runners 
the frequency of AA carriers was significantly lower among elite compared 
to national levels runners suggesting the potential role of the ACSL genotype 
for endurance excellence in this population as well. 
We hypothesized that since endurance trainability is less important for 
short-distances athletic events, the frequency of the ACSL1 single nucleotide 
polymorphism would be lower among sprinters and jumpers. However, in 
contrast to our hypothesis no significant difference was found in the ACSL 
AA genotype between professional Israeli long-distance runners, middle-
distance runners, sprinters and jumpers. The potential contribution of many 
potential genes for excellence in endurance and anaerobic-power type sports 
were studied in recent years, and several favoring endurance and anaero bic-
power single nucleotide polymorphism profiles were proposed [1]. The pre-
sent study suggests that the ACSL1 single nucleotide polymorphism cannot 
distinguish between these two ends of the endurance to sprint 
The potential use of genetic polymorphisms, and in particular the single 
nucleotide polymorphism (SNP) of hormone genes, as a tool to assist in 
predicting future athletic performance is currently an extremely challenging 
topic, mainly because each possible gene makes only a small contribution to 
the overall heritability. Previous results and the results of the present study 
suggest that while the ACSL1 single nucleotide polymorphism may influ-
ence endurance trainability among non-athletic individuals, its role among 
professional athletes is still not clear.
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